The pharmacokinetic and pharmacodynamic properties of vancomycin.

Vancomycin is one of only a few antibiotics available to treat patients infected with methicillin-resistant Staphylococcus aureus and methicillin-resistant, coagulase-negative Staphylococcus species. Therefore, understanding the clinical implications of the pharmacokinetic and pharmacodynamic properties of vancomycin is a necessity for clinicians. Vancomycin is a concentration-independent antibiotic (also referred to as a "time-dependent" antibiotic), and there are factors that affect its clinical activity, including variable tissue distribution, inoculum size, and emerging resistance. This article reviews the pharmacokinetic and pharmacodynamic data related to vancomycin and discusses such clinical issues as toxicities and serum concentration monitoring.

[1]  J. Rotschafer,et al.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations , 1982, Antimicrobial Agents and Chemotherapy.

[2]  R. Brummett,et al.  Vancomycin- and erythromycin-induced hearing loss in humans , 1989, Antimicrobial Agents and Chemotherapy.

[3]  R. Moellering.  Pharmacokinetics of vancomycin. , 1984, The Journal of antimicrobial chemotherapy.

[4]  R. Blouin,et al.  Vancomycin pharmacokinetics in normal and morbidly obese subjects , 1982, Antimicrobial Agents and Chemotherapy.

[5]  G. Matzke,et al.  Clinical Pharmacokinetics of Vancomycin , 1986, Clinical pharmacokinetics.

[6]  M. Rybak,et al.  Effect of Human Serum on Killing Activity of Vancomycin and Teicoplanin against Staphylococcus aureus , 1994, Pharmacotherapy.

[7]  J. Sobel,et al.  Vancomycin, trimethoprim-sulfamethoxazole, and rifampin. , 1995, Infectious disease clinics of North America.

[8]  P. Ward,et al.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Charles G. Martin,et al.  Mississippi mud in the 1990s , 1998, Cancer.

[10]  W. Keane,et al.  Pharmacokinetics of vancomycin in patients with various degrees of renal function , 1984, Antimicrobial Agents and Chemotherapy.

[11]  M. Moore,et al.  Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of Endocarditis , 2003, Antimicrobial Agents and Chemotherapy.

[12]  A. MacGowan,et al.  European Congress of Clinical Microbiology and Infectious Disease , 2004 .

[13]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[14]  K. Fuursted,et al.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model , 1997, Antimicrobial agents and chemotherapy.

[15]  G. Kaatz,et al.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin , 1991, Antimicrobial Agents and Chemotherapy.

[16]  R. Weinstein,et al.  Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Sorrell,et al.  A prospective study of adverse reactions associated with vancomycin therapy. , 1985, The Journal of antimicrobial chemotherapy.

[18]  O. Cars,et al.  In Vitro Studies of Pharmacodynamic Properties of Vancomycin against Staphylococcus aureus andStaphylococcus epidermidis , 1998, Antimicrobial Agents and Chemotherapy.

[19]  G. Drusano,et al.  Antimicrobial Pharmacodynamics in Theory and Clinical Practice , 2007 .

[20]  J. Rotschafer,et al.  The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. , 1996, The Journal of antimicrobial chemotherapy.

[21]  B. Farber,et al.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 , 1983, Antimicrobial Agents and Chemotherapy.

[22]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[23]  D. Bagger-sjöbäck,et al.  An experimental study of vancomycin-induced cochlear damage , 2004, Archives of oto-rhino-laryngology.

[24]  G. Schiffman,et al.  Immune responses to pneumococcal polysaccharide antigens: a comparison of the murine model and the response in humans. , 1981, Reviews of infectious diseases.

[25]  M. Rybak,et al.  Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model , 2004, Antimicrobial Agents and Chemotherapy.

[26]  C. A. Wood,et al.  Vancomycin enhancement of experimental tobramycin nephrotoxicity , 1986, Antimicrobial Agents and Chemotherapy.

[27]  R. Farinotti,et al.  Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[28]  G. Kaatz,et al.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin , 1992, Antimicrobial Agents and Chemotherapy.

[29]  P. Ward,et al.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  J. Sobel,et al.  Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. , 2004, Infectious disease clinics of North America.

[31]  J. Rotschafer,et al.  The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. , 1989, The Journal of burn care & rehabilitation.

[32]  R. Slaughter,et al.  Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. , 1987, The American journal of medicine.

[33]  L. Albrecht,et al.  Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus Aureus , 1991, DICP : the annals of pharmacotherapy.

[34]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[35]  J. Wold,et al.  Toxicology of vancomycin in laboratory animals. , 1981, Reviews of infectious diseases.

[36]  M. Rybak,et al.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside. , 1990, The Journal of antimicrobial chemotherapy.

[37]  W. Bennett,et al.  Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects , 1988, Clinical pharmacology and therapeutics.

[38]  Marlene H. Dortch.  Washington, DC , 1985, International Society of Hair Restoration Surgery.

[39]  B. Bruguerolle,et al.  Cerebrospinal Fluid Penetration and Pharmacokinetics of Vancomycin Administered by Continuous Infusion to Mechanically Ventilated Patients in an Intensive Care Unit , 2000, Antimicrobial Agents and Chemotherapy.

[40]  B. Ackerman,et al.  Vancomycin Serum Protein Binding Determination by Ultrafiltration , 1988, Drug intelligence & clinical pharmacy.

[41]  D. Elliott,et al.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma , 1990, Antimicrobial Agents and Chemotherapy.

[42]  E. Concia,et al.  Penetration of vancomycin into human lung tissue. , 1996, The Journal of antimicrobial chemotherapy.

[43]  H. Chambers,et al.  Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods , 2003, Antimicrobial Agents and Chemotherapy.